{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:17:40Z","timestamp":1786976260549,"version":"build-2736575974"},"reference-count":57,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The study aims to evaluate the clinical outcomes in patients with hypermobility spectrum disorder (HSD) and hypermobile Ehlers\u2013Danlos syndrome (hEDS) with chronic pain following treatment with cannabis\u2010based medicinal products (CBMPs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a case series conducted with the UK Medical Cannabis Registry. The primary outcomes were changes in the following validated patient\u2010reported outcome measures at 1, 3, 6, 12, and 18 months compared with baseline: Short\u2010Form McGill Pain Questionnaire 2 (SF\u2010MPQ\u20102), pain visual analog scale score (Pain\u2010VAS), Brief Pain Inventory (BPI), five\u2010level EQ\u20105D (EQ\u20105D\u20105L), Single\u2010Item Sleep Quality Scale (SQS), General Anxiety Disorder Seven\u2010Item Scale (GAD\u20107), and Patient Global Impression of Change. The incidence of adverse events was analyzed as secondary outcomes. Statistical significance was defined as\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.050.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 161 patients met inclusion criteria. Improvements were observed in BPI severity and interference subscales, SF\u2010MPQ\u20102, and Pain\u2010VAS (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Changes were also seen in the EQ\u20105D\u20105L index value, SQS, and GAD\u20107 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). A total of 50 patients (31.06%) reported one or more adverse event with a total incidence of 601 (373.29%). The most frequent rating for adverse events was moderate (n = 258; 160.25%), with headache being the most common (n = 44; 27.33%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An association was identified between patients with HSD\/hEDS with chronic pain and improvements in pain\u2010specific and general health\u2010related quality of life following the commencement of CBMPs. CBMPs were also well tolerated at 18 months. These findings must be interpreted within the context of the limitations of study design but add further weight to calls for randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr2.70024","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:42:06Z","timestamp":1741851726000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["<scp>UK<\/scp>\n                    Medical Cannabis Registry: An Analysis of Outcomes of Medical Cannabis Therapy for Hypermobility\u2010Associated Chronic Pain"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7195-0900","authenticated-orcid":false,"given":"Mary","family":"Dickinson","sequence":"first","affiliation":[{"name":"Medical Cannabis Research Group, Imperial College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Erridge","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Imperial College London, and Curaleaf Clinic  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Warner\u2010Levy","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Imperial College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evonne","family":"Clarke","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"McLachlan","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Coomber","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic and St. George's Hospital NHS Trust  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Holden","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic, Kings College London, and South London &amp; Maudsley NHS Foundation Trust  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Platt","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael H.","family":"Sodergren","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Imperial College London, and Curaleaf Clinic  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2021.04.200374"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31539"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/dvdy.220"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.33070"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.02.013"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2004.tb02749.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.2.116"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.36315"},{"key":"e_1_2_6_10_1","first-page":"116","article-title":"Hypermobility, the Ehlers\u2010Danlos syndromes and chronic pain","volume":"107","author":"Syx D","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31950"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31554"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000428"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2040"},{"key":"e_1_2_6_15_1","unstructured":"Home Office.Drug licensing factsheet: cannabis CBD and other cannabinoids. GOV.UK. October 3 2024. Accessed January 26 2024.https:\/\/www.gov.uk\/government\/publications\/cannabis\u2010cbd\u2010and\u2010other\u2010cannabinoids\u2010drug\u2010licensing\u2010factsheet\/drug\u2010licensing\u2010factsheet\u2010cannabis\u2010cbd\u2010and\u2010other\u2010cannabinoids"},{"key":"e_1_2_6_16_1","volume-title":"The Health Effects of Cannabis and Cannabinoids: the Current State of Evidence and Recommendations for Research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1034"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001941"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001929"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.613805"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1056438"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242568"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2023.2174633"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-021-00346-0"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2183841"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2181696"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2195551"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/1468-2230.12669"},{"key":"e_1_2_6_29_1","volume-title":"The Supply, Manufacture, Importation and Distribution of Unlicensed Cannabis\u2010Based Products for Medicinal Use in Humans \u2018Specials","author":"Medicines and Healthcare Products Regulatory Agency","year":"2020"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_2_6_31_1","unstructured":"International Standard Classification of Occupations (ISCO).International Labour Organization.2008. January 26 2024.https:\/\/ilostat.ilo.org\/methods\/concepts-and-definitions\/classification-occupation\/."},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_6_33_1","unstructured":"Medicines and Healthcare Products Regulatory Agency;Department of Health and Social Care.Good manufacturing practice and good distribution practice. GOV.UK. Updated May 13 2014. Accessed January 26 2024.https:\/\/www.gov.uk\/guidance\/good-manufacturing-practice-and-good-distribution-practice"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2023.2174633"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aet124"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.02.007"},{"key":"e_1_2_6_37_1","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland CS","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"e_1_2_6_38_1","author":"Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials","year":"2019","journal-title":"IMMPACT."},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000933"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0962-1105.2003.00365.x"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.7478"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318160d093"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.01.032"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1378"},{"key":"e_1_2_6_49_1","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","author":"National Cancer Institute","year":"2009"},{"key":"e_1_2_6_50_1","first-page":"11","article-title":"A closer look at the baseline\u2010observation\u2010carried\u2010forward (BOCF)","volume":"4","author":"Liu\u2010Seifert H","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774515602688"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.856"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3072"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43848"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1159\/000489291"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.140"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.10.001"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.07.014"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.70024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:23:30Z","timestamp":1759415010000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.70024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/acr2.70024"],"URL":"https:\/\/doi.org\/10.1002\/acr2.70024","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70024"}}